Clinical Trial Update: 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating 177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-I&T (177Lu-PSMA-I&T)

Snippet

Sponsor: Curium US LLC | Conditions: Metastasis From Malignant Tumor of Prostate | Phase 3 | Status: ACTIVE_NOT_RECRUITING